KOSDAQChemicals344860

Innogene

₩1,232▼ 2.07%2026-11-18 close
Market Cap
₩18.5B
Turnover
₩17,573,677
Volume
10K
Shares out.
15M
PER
—
PBR
0.9×
EPS
-₩32
Dividend Yield
6.92%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩90 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Recovers, Losses Persist; Margin Repair Is the Test

Quarterly revenue in 2026 has risen sharply, but operating losses have continued for three straight quarters from the first quarter through the third, making the recovery of profitability the key point to watch.

  1. 1

    Revenue peaked at KRW 10.1 billion in 2023 and then fell for two consecutive years to KRW 8.21 billion in 2025.

  2. 2

    The operating margin fell from 16.3% in 2022 to 0.1% in 2025, and operating profit declined for three consecutive years from 2023 through 2025.

  3. 3

    Second-quarter 2026 revenue reached KRW 4.8 billion, up 85.1% from the prior quarter, and third-quarter revenue of KRW 3.55 billion rose 66.2% year on year, while the operating loss narrowed to KRW 123 million from KRW 530 million.

  4. 4

    To enter the care-food market, the company signed an MOU in June 2026 with a natural-extract technology partner and plans to launch care-food products in sequence.

  5. 5

    At the end of 2025 the debt-to-equity ratio was 6.7% with total equity of KRW 14.1 billion, and the price-to-book ratio sits below 1x; completion of a buyback of 717,435 shares totaling KRW 1 billion was disclosed on November 12, 2026.

02

Business structure

Innogene was founded in 2005 as a cosmeceutical company focused on hair loss, problem skin and skin regeneration, and listed on KOSDAQ in February 2023.

It supplies home-care products, scalp care devices, health functional foods and pharmaceutical solutions to clinics in Korea, and according to its company profile it exports to about 20 countries, including the United States and China.

Its core line is the hair-loss symptom relief products centered on the BALLVIC brand, offered as a system combined with scalp care devices. Skin-beauty products and hair-loss products form the two main pillars of revenue.

In 2026 a raw farm-produce supply business for care food was added; the company said one month of supply in March 2026 generated KRW 699 million in new revenue, as announced on June 11, 2026.

In the same month it signed an MOU with a partner specializing in functional ingredient infusion from natural extracts and agreed to jointly develop premium care-food products using natural raw materials such as tomato and black soybean.

The company has presented a strategy of widening its focus from cosmetics and medical devices toward ingestible anti-aging products. For China, it runs marketing linked with ISCE, a brand selected among China's top 100.

The company is classified under chemicals, but its operations are closer to consumer cosmeceuticals than to the petrochemical business of large peers such as LG Chem. Whether revenue mix shifts from hair and skin products toward raw materials and care food is a point to track in the annual report.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.1B-₩29,829,398−1.4%
2025Q4₩2.4B₩100M4.5%
2026Q1₩2.6B-₩200M−6.8%
2026Q2₩4.8B-₩500M−11.0%
2026Q3₩3.6B-₩100M−3.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.1B₩1.5B₩1.3B16.3%19.9%17.9%
2023₩10.1B₩1.2B₩1.4B12.1%8.7%7.3%
2024₩8.9B₩600M₩900M7.0%5.7%5.6%
2025₩8.2B₩4,492,321₩300M0.1%2.0%6.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 9.14 billion in 2022 to KRW 10.1 billion in 2023, up 10.5% year on year, then declined to KRW 8.94 billion in 2024, down 11.4%, and to KRW 8.21 billion in 2025, down 8.2%. Among 2022 to 2025, 2023 was the largest year and 2025 the smallest.

Operating profit went from KRW 1.49 billion in 2022 to KRW 1.23 billion in 2023, down 17.6%, then to KRW 630 million in 2024, down 48.6%, and to KRW 4.49 million in 2025, down 99.3%, and it declined for three consecutive years from 2023 through 2025.

The operating margin fell from 16.3% in 2022 to 12.1% in 2023, 7.0% in 2024 and 0.1% in 2025. For 2025 the company attributed the decline to a smaller revenue base across domestic and export sales, which left fixed costs relatively heavier.

Net profit attributable to controlling shareholders was KRW 1.34 billion in 2022, KRW 1.4 billion in 2023 (up 4.2%), KRW 945 million in 2024 (down 32.3%) and KRW 288 million in 2025 (down 69.5%), with two consecutive annual declines from 2024.

Net income including non-controlling interests was reported at the same levels, following the same path. Operating cash flow was KRW 585 million in 2022, KRW 2.24 billion in 2023, KRW 809 million in 2024 and KRW 704 million in 2025.

Total equity at the end of 2025 was KRW 14.1 billion, total liabilities were KRW 939 million, and the debt-to-equity ratio was 6.7%.

On a quarterly basis, the third quarter of 2025 showed revenue of KRW 2.14 billion and an operating loss of KRW 29.83 million, while the fourth quarter brought revenue of KRW 2.41 billion, up 13.0% from the prior quarter, and an operating profit of KRW 109 million, a swing back into profit.

First-quarter 2026 revenue was KRW 2.59 billion, up 7.3% from the prior quarter, but the operating loss of KRW 176 million marked a return to loss. Second-quarter 2026 revenue jumped to KRW 4.8 billion, yet the operating loss widened to KRW 530 million.

Third-quarter revenue was KRW 3.55 billion, down 25.9% from the prior quarter and up 66.2% year on year, and the operating loss narrowed to KRW 123 million.

Net profit attributable to controlling shareholders was KRW 211 million in the fourth quarter of 2025, then a net loss of KRW 96.11 million in the first quarter of 2026, KRW 472 million in the second quarter and KRW 19.87 million in the third quarter, three straight loss-making quarters.

The net loss attributable to controlling shareholders over the last four quarters totaled KRW 377 million. The company described the first-quarter loss as the cost of strategic investment in digital marketing, its own distribution mall infrastructure and overseas marketing.

05

Industry analysis

Innogene operates in cosmeceuticals centered on hair-loss and scalp care and skin regeneration. Although it is classified under chemicals, its demand drivers differ from the petrochemical cycle and are closer to consumer spending and clinic-channel demand.

Industry coverage repeatedly points to rising spending on appearance and anti-aging concerns as living standards improve.

The anti-aging market is widening from cosmetics and medical devices toward ingestible products such as care food and inner-beauty items, and Innogene added a raw-material care-food business in line with this shift.

Overseas, its export structure spans about 20 countries including the United States and China, so marketing linked to China and expansion of overseas channels are key variables for results.

In hair and scalp care, several companies sell through clinics, and Innogene runs both clinic supply and its own distribution mall, MP Mall.

Large chemical peers such as LG Chem and Hanwha Solutions focus on large-scale petrochemicals and battery materials, so their sales scale and profit structure are hard to compare directly. The company presents its differentiation as a broader product lineup linking hair-care devices and care food. Because its revenue base is small, adding lines can also amplify quarter-to-quarter revenue swings.

06

Outlook

When it announced first-quarter 2026 results, the company said that building marketing and distribution foundations in the first quarter would bring a full-scale earnings rebound from the second half. It also said a new scalp-care device using its own technology is scheduled for launch in the second half.

Following its June 2026 MOU, it agreed to launch care-food products in sequence and jointly develop them with the partner. The company said one month of raw farm-produce supply in March 2026 generated KRW 699 million in new revenue and expected the new revenue stream to support growth over the medium to long term.

In the quarterly record, second-quarter 2026 revenue of KRW 4.8 billion and third-quarter revenue of KRW 3.55 billion show a much larger top line. However, operating losses persisted for three straight quarters from the first quarter through the third, and the loss widened to KRW 530 million in the second quarter.

The company bought back 717,435 shares for a total of KRW 1 billion between August 12 and November 10, 2026, and disclosed completion on November 12, 2026. This is a shareholder-return fact that should be read alongside the earnings trend.

The next points to confirm are whether second-half new products and care-food sales show up in quarterly results, and how far the operating margin recovers from 0.1% in 2025 in the 2026 annual report.

07

Valuation

PER
—
PBR
0.9×
ROE
-2.5%
EPS
-₩32
BPS
₩1,434
Dividend per share
₩90

Because the net loss attributable to controlling shareholders over the last four quarters exceeds the profits, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits below 1x, meaning the shares trade under the book value of net assets.

Total equity is KRW 14.1 billion with a small debt load, so the balance sheet carries little burden relative to net assets, but the operating profit those assets generate has fallen sharply since 2025.

Cash dividends have continued even as earnings have shrunk, so whether dividends can be sustained is the central shareholder-return question. Comparing the operating margin of 16.3% in 2022 with 0.1% in 2025 shows a large decline in profitability.

Direct multiple comparisons with large chemical peers are limited because the business structures differ widely. Reading the multiples depends on whether operating profit returns to the black and when quarterly losses end, so the turn to profit is the reference point for valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Care food widens the revenue base

In June 2026 the company signed an MOU with a natural-extract technology partner and entered the care-food market, with products to launch in sequence. It said one month of raw farm-produce supply in March 2026 generated KRW 699 million in new revenue. Adding a revenue stream beyond its hair and skin products is cited as a bullish factor.

Quarterly revenue scale has expanded

Second-quarter 2026 revenue of KRW 4.8 billion is well above the KRW 2.14 billion of the third quarter of 2025 and the KRW 2.41 billion of the fourth quarter. Third-quarter revenue of KRW 3.55 billion rose 66.2% year on year, and the operating loss narrowed to KRW 123 million from KRW 530 million. A broader quarterly revenue base alongside a smaller loss is the positive trend.

Low debt and share repurchase

At the end of 2025 the debt-to-equity ratio was 6.7%, with total liabilities of KRW 939 million and total equity of KRW 14.1 billion. The company bought back 717,435 shares for a total of KRW 1 billion between August 12 and November 10, 2026, and disclosed completion on November 12, 2026. Its low borrowing burden is cited as a strength that leaves room to keep funding new businesses.

09

Bear factors

Marked erosion of profitability

Operating profit of KRW 4.49 million in 2025 was down 99.3% from the prior year. The company attributed this to a smaller revenue base that left fixed costs heavier, so whether revenue recovery converts into profit is the central bearish question.

Consecutive quarterly losses

Operating losses persisted for three straight quarters from the first quarter through the third of 2026, and the net loss attributable to controlling shareholders also ran three straight quarters.

The company described the first-quarter loss as investment in marketing and distribution infrastructure, but the operating loss widened to KRW 530 million in the second quarter.

Large swings in quarterly revenue

Revenue of KRW 4.8 billion in the second quarter of 2026 was far above the KRW 2.59 billion of the first quarter, but in the third quarter it fell 25.9% from the prior quarter to KRW 3.55 billion. Such sharp quarter-to-quarter moves make the continuity of the earnings trend hard to judge. Whether raw-material care-food sales recur each quarter needs to be confirmed in periodic reports.

10

Risk factors

Product and channel concentration

Revenue is concentrated in hair-loss symptom relief products and the BALLVIC brand. Because the structure relies on clinic channels and exports, changes in channel policy or overseas demand could have an impact. Care-food launch timing may shift depending on joint development schedules with the partner.

Cost burden and cash flow

Marketing and personnel costs tied to new businesses and brand expansion are flowing through 2026 quarterly results. Operating cash flow fell from KRW 2.24 billion in 2023 to KRW 704 million in 2025. If losses persist, the capacity for shareholder returns such as cash dividends and share buybacks could narrow.

Small-cap profile and overseas regulation

With a small market capitalization, the share price can be volatile and trading may be thin. Because marketing linked to China and overseas channels matter, local regulation and currency movements are also variables. Changes in rules for cosmetics and health functional foods could affect the pace of the care-food business.

11

What to watch next

  1. December 2026

    Whether the new scalp-care device scheduled for the second half of 2026 launches. The question is whether quarterly revenue and operating loss follow the narrowing trend seen in the third quarter.

  2. Second half of 2026

    Sequential launch of care-food products developed with the partner and whether they show up in revenue. The key test is whether care food becomes a stable new revenue source.

  3. Early February 2027

    Preliminary full-year 2026 results. The 2025 annual results were disclosed on February 5, 2026, and the question is whether the fourth quarter of 2026 moves out of operating losses.

  4. By late March 2027

    Filing of the 2026 annual report. The points to check are how far the operating margin recovered from 0.1% in 2025, and whether quarterly revenue mix and the care-food share are disclosed.

  5. Mid-May 2027

    First-quarter 2027 results. Based on the 2026 pattern of announcing first-quarter results on May 15, the question is whether quarterly losses extend to a fourth consecutive quarter.

12

Overall view

Innogene is a cosmeceutical company centered on hair-loss and skin care. Revenue has declined since 2023, operating profit fell for three consecutive years from 2023 through 2025, and the operating margin dropped to 0.1% in 2025.

Quarterly revenue scale expanded sharply in 2026, and the business is widening with care food and a new scalp-care device.

However, operating losses persisted for three straight quarters from the first quarter through the third of 2026, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 377 million.

The balance sheet carries a debt-to-equity ratio of 6.7% and total equity of KRW 14.1 billion, so the burden is modest, and the price-to-book ratio sits below 1x. Bullish factors are the revenue recovery and financial capacity, while bearish factors are weaker profitability and persistent quarterly losses.

The points to confirm now are the revenue contribution of second-half products and care food, the operating margin in the 2026 annual report, and whether dividends and share repurchases continue while earnings shrink.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. butler.works
  4. news.nate.com
  5. digitaltoday.co.kr
  6. m.news.nate.com
  7. pharm.edaily.co.kr
  8. sedaily.com
  9. tradingkey.com
  10. news.nate.com
  11. tradingkey.com
  12. edaily.co.kr
  13. newspim.com
  14. digitaltoday.co.kr
  15. m.news.nate.com
  16. hyundaimotorgroup.com
  17. news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis